Literature DB >> 8770880

Role of aldosterone in the remnant kidney model in the rat.

E L Greene1, S Kren, T H Hostetter.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) participates in the injury sustained by the remnant kidney. Our studies assessed the importance of aldosterone in that model and the response of aldosterone to drugs interfering with the RAAS. Initially, four groups of rats were studied: SHAM-operated rats, untreated remnant rats (REM), REM rats treated with losartan and enalapril (REM AIIA), and REM AIIA rats infused with exogenous aldosterone (REM AIIA + ALDO). The last group was maintained with aldosterone levels comparable to those in untreated REM rats by constant infusion of exogenous aldosterone. REM rats had larger adrenal glands and a > 10-fold elevation in plasma aldosterone compared to SHAM. REM AIIA rats demonstrated significant suppression of the hyperaldosteronism as well as marked attenuation of proteinuria, hypertension, and glomerulosclerosis compared to REM. REM AIIA + ALDO rats manifested greater proteinuria, hypertension, and glomerulosclerosis than REM AIIA rats. Indeed, by 4 wk of observation all of these features of the experimental disease were similar in magnitude in REM AIIA + ALDO and untreated REM. In separate REM rats spironolactone administration did not reduce glomerular sclerosis but did transiently reduce proteinuria, lowered arterial pressure, and lessened cardiac hypertrophy. In summary, aldosterone contributes to hypertension and renal injury in the remnant kidney model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770880      PMCID: PMC507523          DOI: 10.1172/JCI118867

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Experimentally induced chronic renal insufficiency in the rat.

Authors:  A B MORRISON
Journal:  Lab Invest       Date:  1962-04       Impact factor: 5.662

2.  N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation.

Authors:  M L Purkerson; D M Tollefsen; S Klahr
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

3.  Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses.

Authors:  M E Ullian; J R Schelling; S L Linas
Journal:  Hypertension       Date:  1992-07       Impact factor: 10.190

4.  Experimental aldosterone hypertension in the dog.

Authors:  Y J Pan; D B Young
Journal:  Hypertension       Date:  1982 Mar-Apr       Impact factor: 10.190

Review 5.  Hypertension-related renal injury: a major contributor to end-stage renal disease.

Authors:  W G Walker
Journal:  Am J Kidney Dis       Date:  1993-07       Impact factor: 8.860

6.  Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.

Authors:  R A Lafayette; G Mayer; S K Park; T W Meyer
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Calcium antagonists inhibit elevated potassium efflux from aorta of aldosterone-salt hypertensive rats.

Authors:  J M Smith; A W Jones
Journal:  Hypertension       Date:  1990-01       Impact factor: 10.190

8.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

Authors:  C G Brilla; K T Weber
Journal:  J Lab Clin Med       Date:  1992-12

9.  Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen.

Authors:  M Wakisaka; M J Spiro; R G Spiro
Journal:  Diabetes       Date:  1994-01       Impact factor: 9.461

10.  Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action.

Authors:  M Wehling; M Christ; K Theisen
Journal:  Am J Physiol       Date:  1992-11
View more
  109 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 3.  Remission of renal disease: recounting the challenge, acquiring the goal.

Authors:  Barry M Brenner
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 4.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

Review 5.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

6.  Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.

Authors:  Chunhua Zhu; Songming Huang; Yanggang Yuan; Guixia Ding; Ronghua Chen; Bicheng Liu; Tianxin Yang; Aihua Zhang
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 7.  Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

Authors:  Niels Holmark Andersen; Carl Erik Mogensen
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

8.  Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.

Authors:  Wei Liang; Cheng Chen; Jing Shi; Zhilong Ren; Fengqi Hu; Harry van Goor; Pravin C Singhal; Guohua Ding
Journal:  Nephrol Dial Transplant       Date:  2010-08-20       Impact factor: 5.992

Review 9.  Antihypertensive drugs and the kidney.

Authors:  Mitra K Nadim; Renee Dua; Vito M Campese
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 10.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.